Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
ALPHA TEKNOVA Aktie jetzt für 0€ handeln | |||||
Mi | Teknova and Pluristyx join hands to streamline next-generation cell therapy production | 3 | Seeking Alpha | ||
Mi | Alpha Teknova, Inc.: Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies | 1 | GlobeNewswire (USA) | ||
07.03. | Alpha Teknova, Inc. - 10-K, Annual Report | - | SEC Filings | ||
05.03. | Alpha Teknova stock holds as KeyBanc maintains rating | 1 | Investing.com | ||
04.03. | Alpha Teknova, Inc. Q4 Loss Narrows | 1 | RTTNews | ||
04.03. | Alpha Teknova, Inc.: Teknova Reports Fourth Quarter and Full Year 2024 Financial Results | 338 | GlobeNewswire (Europe) | Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidanceFourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior yearCompany provides... ► Artikel lesen | |
04.03. | Alpha Teknova, Inc. - 8-K, Current Report | - | SEC Filings | ||
20.02. | Alpha Teknova, Inc.: Teknova to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 | 1 | GlobeNewswire (USA) | ||
12.02. | Here's What Boosted Alpha Teknova (TKNO) in Q4 | 1 | Insider Monkey | ||
10.02. | Craig-Hallum initiates Alpha Teknova stock with buy rating | 1 | Investing.com | ||
08.11.24 | Alpha Teknova, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
08.11.24 | Alpha Teknova GAAP EPS of -$0.15, revenue of $9.6M | 1 | Seeking Alpha | ||
07.11.24 | Alpha Teknova, Inc. - 8-K, Current Report | - | SEC Filings | ||
24.10.24 | Alpha Teknova, Inc.: Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024 | 1 | GlobeNewswire (USA) | ||
09.07.24 | Alpha Teknova, Inc.: Teknova Provides Strategic Business Update and Announces Preliminary Second Quarter 2024 Results | 394 | GlobeNewswire (Europe) | Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova... ► Artikel lesen | |
13.05.24 | Alpha Teknova, Inc.: Teknova Reports First Quarter 2024 Financial Results | 384 | GlobeNewswire (Europe) | First quarter 2024 total revenue was $9.3 million, up 2% from prior yearLaunch of Build-Tek Custom ConfiguratorCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., May 13,... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
TEMPUS AI | 50,23 | 0,00 % | Tempus AI Surges 40% YTD: Are New Strategic Deals a Buy Signal? | ||
ARCUTIS BIOTHERAPEUTICS | 16,450 | 0,00 % | What's Going On With Arcutis Biotherapeutics Stock Monday? | ||
SPRINGWORKS THERAPEUTICS | 49,900 | 0,00 % | SpringWorks Shares Rise More Than 30% in 3 Months: Here's Why | ||
RECURSION PHARMACEUTICALS | 6,850 | 0,00 % | Recursion Pharmaceuticals' Options: A Look at What the Big Money is Thinking | ||
QUANTUM-SI | 1,715 | 0,00 % | Quantum-Si Incorporated: Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK | Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, announces its participation in the upcoming Festival of Genomics UK, taking place on... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 33,740 | 0,00 % | Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025 | ||
BEAM THERAPEUTICS | 24,460 | 0,00 % | Citi lifts Beam Therapeutics stock price target to $64 | ||
EVOTEC | 6,700 | +3,40 % | 100 %-Rally im Anflug? Evotec, D-Wave und KI-Perle NetraMark Aktie | Der Selloff im Tech-Sektor hält auch zum Wochenbeginn an. Ändert sich das Sentiment, könnte eine 100 %-Rally starten. Dies erwarten jedenfalls Analysten bei D-Wave. Insgesamt sehen Analysten den Quantum-Star... ► Artikel lesen | |
ADMA BIOLOGICS | 18,820 | 0,00 % | Will ADMA Biologics Stock Continue Its Momentum in 2025? | ||
QIAGEN | 36,670 | +1,06 % | Biotech Report: Evotec und Qiagen wenig bewegt | (shareribs.com) Frankfurt / New York 13.03.2025 - Biotech-Aktien bewegen sich im deutschen Handel überwiegend im Plus. Evotec und Qiagen notieren kaum verändert. Biontech klettern. An der Wall Street... ► Artikel lesen | |
REGENCELL BIOSCIENCE | 18,840 | 0,00 % | Regencell Bioscience Stock Surges 126% | ||
NUVALENT | 76,56 | 0,00 % | UBS lifts Nuvalent stock rating, maintains $100 price target | ||
SUMMIT THERAPEUTICS | 20,225 | 0,00 % | Summit Therapeutics issues stock options to new employees | ||
DYNE THERAPEUTICS | 12,400 | 0,00 % | Dyne: Phase 1/2 Trial Of DYNE-251 In DMD Shows Sustained Functional Improvements Through 18 Months | WASHINGTON (dpa-AFX) - Dyne Therapeutics Inc. (DYN) announced new long-term clinical data from its Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement... ► Artikel lesen | |
BIONTECH | 92,15 | -1,13 % | Umschichtung von USA nach Europa - BioNTech, Evotec, Vidac Pharma | Die Sanktionspolitik der US-Administration unter US-Präsident Donald Trump schlägt sich langsam bei den US-Indizes durch. Seit der Wahl im November 2024 stagniert der Dow Jones auf hohem Niveau, während... ► Artikel lesen |